Skye Bioscience (SKYE) grants director Deborah Charych 35,000 stock options

Rhea-AI Filing Summary

Skye Bioscience director Deborah H. Charych received stock options for 35,000 shares of common stock. The options have an exercise price of $0.82 per share and were granted on February 6, 2026. They vest in equal monthly installments over a one-year period beginning January 19, 2026, and expire on February 6, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charych Deborah H.

(Last) (First) (Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		35,000		(1)	02/06/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Skye Bioscience (SKYE) disclose in this Form 4 filing?

Skye Bioscience disclosed that director Deborah H. Charych received stock options for 35,000 shares of common stock. The options were granted on February 6, 2026 with a $0.82 exercise price per share and expire on February 6, 2036, subject to monthly vesting.

How many Skye Bioscience (SKYE) stock options were granted to Deborah H. Charych?

Deborah H. Charych was granted stock options covering 35,000 shares of Skye Bioscience common stock. These options vest in equal monthly installments over one year starting January 19, 2026, and give her the right to buy shares at a fixed $0.82 exercise price.

What is the exercise price of the new Skye Bioscience (SKYE) stock options?

The granted stock options have an exercise price of $0.82 per share. This means Deborah H. Charych can purchase up to 35,000 Skye Bioscience common shares at $0.82 each once the options vest, with the options expiring on February 6, 2036 if not exercised.

When do Deborah H. Charych’s Skye Bioscience (SKYE) options vest?

The stock options vest in equal monthly installments over a one-year period beginning January 19, 2026. Each month, a portion of the 35,000 options becomes exercisable until the full grant is vested, provided service conditions for vesting are satisfied during that year.

What is the expiration date of the Skye Bioscience (SKYE) stock options granted?

The stock options granted to Deborah H. Charych expire on February 6, 2036. After that date, any unexercised portion of the 35,000 options can no longer be used to purchase Skye Bioscience common stock at the fixed $0.82 per share exercise price.

Is the Skye Bioscience (SKYE) option grant held directly or indirectly?

The Form 4 indicates the 35,000 stock options are held with direct ownership. The filing lists the ownership form as “D” for direct, meaning the options are attributed directly to Deborah H. Charych rather than to an intermediary entity or related account.